CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Crizanlizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04611880
NCT04611880Phase 2Completed
CompareCT.gov

A Trial of Crizanlizumab for the Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)

Washington University School of Medicine·interventional·Posted Nov 2, 2020·Updated Apr 23, 2026

In Brief

A Phase 2 clinical trial evaluating Crizanlizumab for RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy. Completed, enrolled 18 participants across 2 sites.

Detailed Summary

This is a Phase 2 trial that will test the efficacy and safety of crizanlizumab for the treatment of retinal vasculopathy with cerebral leukoencephalopathy (RVCL), a very rare and uniformly fatal genetic condition that affects the microvasculature, especially of the brain and eye. There currently is no treatment for RVCL. A maximum of 20 patients will be enrolled.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedNov 2, 2020
Enrollment StartJan 25, 2021
Primary CompletionApr 2, 2025
Study CompletionDec 31, 2025
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 5.7 years ago

Interventions

Crizanlizumabdrug

Drug: crizanlizumab is a humanized monoclonal anti-P-selectin antibody that prevents leukocyte adhesion to the vascular endothelium, thereby limiting risk of microvascular occlusion. It is administered intravenously.